

GLUCADEX 2 MG/ML SOLUTION FOR INJECTION FOR HORSES, CATTLE, GOATS, PIGS, DOGS AND CATS

Authorised

- Dexamethasone sodium phosphate

Product identification

Medicine name:

GLUCADEX 2 MG/ML SOLUTION FOR INJECTION FOR HORSES, CATTLE, GOATS, PIGS, DOGS AND CATS

Active substance:

Dexamethasone sodium phosphate

Target species:

Cattle

Pig

Cat

Horse

Goat

Dog

Route of administration:

Intramuscular use

Subcutaneous use

Periarticular use
Intravenous use
Intraarticular use

Product details

Active substance and strength:

Dexamethasone sodium phosphate
2.63 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Cattle

- Meat and offal. 8 day
- Milk. 72 hour

-

Pig

- Meat and offal. 2 day

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorized for use in horses producing milk for human consumption.

-

Goat

- Meat and offal. 8 day
- Milk. 72 hour

Periarticular use:

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorized for use in horses producing milk for human consumption.

Intravenous use:

-

Cattle

- Meat and offal. 8 day
- Milk. 72 hour

-

Pig

- Meat and offal. 6 day

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorized for use in horses producing milk for human consumption.

-

Goat

- Meat and offal. 8 day
- Milk. 72 hour

Intraarticular use:

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorized for use in horses producing milk for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QH02AB02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Package description:

Box with 1 bottle of 50 ml

Bow with 1 bottle of 100 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Kepro B.V.

Marketing authorisation date:

24/02/2020

Manufacturing sites for batch release:

Kepro B.V.

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 124033

Date of authorisation status change:

5/04/2022

Reference member state:

France

Procedure number:

FR/V/0374/001

Concerned member states:

Belgium Bulgaria Germany Greece Ireland Italy Luxembourg Netherlands
Poland Romania Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 14/03/2026

[Download](#)

eu-puar-frv0374001-mr-rpe547-en.pdf